Highlights

MediaPharma S.r.l.
A Company focused on the discovery and development of innovative drugs for the treatment of cancer and other diseases with unmet medical need.

MP-LG1&LG2

 

Human recombinant therapeutic proteins

 

LG1 & LG2 are human recombinant therapeutic proteins which  represent an innovative treatment for Non-Healing Wounds and Peripheral Arterial Disease.

Scientists at MediaPharma have discovered recombinant proteins, named LG1 & LG2, which accelerate wound healing through stimulation of angiogenesis and adhesion via an innovative mechanism.

MediaPharma is sought to develop an application of these products in:

  • Diabetic foot ulcers
  • Non-healing surgical wounds
  • Wounds related to metabolic diseases
  • Wounds that repeatedly break down

Administration of these proteins in a murine model of Hind Limb Hischemia (HLI) has shown a significant acceleration of blood flow recovery in the affected limb compared to vehicle treated controls. 

MediaPharma is sought to develop an application of these products in:

  • Acute and chronic peripheral arteropathy
  • Lower limb ischemia with foot ulcer (diabetic/non-diabetic)

 

I commenti sono chiusi.

Company

R&D

Careers

Business